Cargando…
TRPV1 antagonist JNJ-39439335 (mavatrep) demonstrates proof of pharmacology in healthy men: a first-in-human, double-blind, placebo-controlled, randomized, sequential group study
This double-blind, randomized, placebo-controlled, sequential group, phase 1 study was designed to assess in healthy men, the safety, tolerability, pharmacokinetics, and translational pharmacodynamics of JNJ-39439335 (mavatrep), a transient receptor potential vanilloid subtype 1 antagonist; it was p...
Autores principales: | Manitpisitkul, Prasarn, Brandt, Michael, Flores, Christopher M., Kenigs, Velga, Moyer, John A., Romano, Gary, Shalayda, Kevin, Mayorga, Arthur J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741288/ https://www.ncbi.nlm.nih.gov/pubmed/29392196 http://dx.doi.org/10.1097/PR9.0000000000000576 |
Ejemplares similares
-
Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
por: Salvadore, Giacomo, et al.
Publicado: (2020) -
TRPV1 Antagonists and Chronic Pain: Beyond Thermal Perception
por: Brandt, Michael R., et al.
Publicado: (2012) -
Dataset of eyeblink conditioning in mice treated with the selective mGluR1 antagonist JNJ16259685
por: Tohyama, Shoichi, et al.
Publicado: (2023) -
A Selective Histamine H4 Receptor Antagonist, JNJ7777120, Role on glutamate Transporter Activity in Chronic Depression
por: Yeni, Yesim, et al.
Publicado: (2022) -
A Selective Histamine H(4) Receptor Antagonist, JNJ7777120, Is Protective in a Rat Model of Transient Cerebral Ischemia
por: Dettori, Ilaria, et al.
Publicado: (2018)